Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676142 | 0.97 | LMNA (0.82) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL30535283 | 0.97 | LMNA (0.82) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL16114401 | 0.92 | LMNA (0.75) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL78141 | 0.90 | LMNA (0.72) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL29500180 | 0.90 | LMNA (0.72) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL22061921 | 0.90 | LMNA (0.87) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| Bromide SCHEMBL9391382 | 0.88 | LMNA (0.69) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL27968872 | 0.88 | LMNA (0.69) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL9386460 | 0.88 | LMNA (0.69) | LMNATDP1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11107948 | 0.83 | LMNA (0.62) | LMNATDP1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| EP-0873123-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| EP-0873123-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | LMNA 1946/4885TDP1 3740/4885CYP19A1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.